CLOs on the Move

BioDelivery Sciences International

www.bdsi.com

 
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.bdsi.com
  • 4131 Parklake Avenue Suite 225
    Raleigh, NC USA 27612
  • Phone: 919.582.9050

Executives

Name Title Contact Details
James Vollins
General Counsel, Chief Compliance Officer, and Corporate Secretary Profile

Similar Companies

Axcan Pharma Inc

Axcan Pharma Inc is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Calliditas

Calliditas is a specialty pharmaceutical company developing high value products for patients with significant unmet medical needs. With a highly experienced, dynamic management team, Calliditas draws on its extensive experience of pharmaceutical development and marketing to efficiently identify and progress valuable and de-risked products.

Janssen-Ortho

Janssen-Ortho Inc. is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Sanofi

3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.

Oramed

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).